Yacoub A Yousef1, Amal M Noureldin1, Iyad Sultan2, Rasha Deebajah2, Maysa Al-Hussaini3, Munir Shawagfeh4, Mustafa Mehyar1, Mona Mohammad1, Imad Jaradat5, Ibrahim AlNawaiseh1. 1. Departments of Surgery/Ophthalmology, King Hussein Cancer Centre (KHCC), Queen Rania Al-Abdullah Street, P.O. Box 1269, Amman 11941, Jordan. 2. Pediatrics Oncology, King Hussein Cancer Centre (KHCC), Queen Rania Al-Abdullah Street, P.O. Box 1269, Amman 11941, Jordan. 3. Pathology, King Hussein Cancer Centre (KHCC), Queen Rania Al-Abdullah Street, P.O. Box 1269, Amman 11941, Jordan. 4. Anesthesia, King Hussein Cancer Centre (KHCC), Queen Rania Al-Abdullah Street, P.O. Box 1269, Amman 11941, Jordan. 5. Radiation Oncology, King Hussein Cancer Centre (KHCC), Queen Rania Al-Abdullah Street, P.O. Box 1269, Amman 11941, Jordan.
Abstract
OBJECTIVE: To evaluate our experience with intravitreal melphalan chemotherapy as a second-line regimen for RB patients with refractory or recurrent vitreous seeds. METHODS: A retrospective case series of 16 eyes from 16 patients with intraocular RB who received intravitreal melphalan chemotherapy using the antireflux injection technique. Data included demographics, stage at diagnosis, treatment modalities, side effects, eye salvage, and survival. RESULTS: The total number of injections was 64 (median, 3 injections per eye; range, 3-8), and the median age at time of injection was 22 months (range, 9-63 months). Nine (56%) patients were males, and 13 (81%) patients had bilateral RB. Complete response was seen in 13 (81%) eyes: in 9 (100%) eyes with focal vitreous seeds and in 4 (57%) eyes with diffuse vitreous seeds (P=0.062). At a median follow-up of 18 months (range, 6-48 months), the eye salvage rate was 81%, local retinal toxicity confined to the site of injection was seen in 2/3 of the eyes, 2 (12%) eyes had cataract, and none of the patients had orbital recurrence and distant metastasis or was dead. CONCLUSION: Intravitreal melphalan is a promising modality for treatment of vitreous seeds, and the dose of 20-30 μg of melphalan sounds to be safe and effective for refractory and recurrent vitreous seeds.μg of melphalan sounds to be safe and effective for refractory and recurrent vitreous seeds.
OBJECTIVE: To evaluate our experience with intravitreal melphalan chemotherapy as a second-line regimen for RB patients with refractory or recurrent vitreous seeds. METHODS: A retrospective case series of 16 eyes from 16 patients with intraocular RB who received intravitreal melphalan chemotherapy using the antireflux injection technique. Data included demographics, stage at diagnosis, treatment modalities, side effects, eye salvage, and survival. RESULTS: The total number of injections was 64 (median, 3 injections per eye; range, 3-8), and the median age at time of injection was 22 months (range, 9-63 months). Nine (56%) patients were males, and 13 (81%) patients had bilateral RB. Complete response was seen in 13 (81%) eyes: in 9 (100%) eyes with focal vitreous seeds and in 4 (57%) eyes with diffuse vitreous seeds (P=0.062). At a median follow-up of 18 months (range, 6-48 months), the eye salvage rate was 81%, local retinal toxicity confined to the site of injection was seen in 2/3 of the eyes, 2 (12%) eyes had cataract, and none of the patients had orbital recurrence and distant metastasis or was dead. CONCLUSION: Intravitreal melphalan is a promising modality for treatment of vitreous seeds, and the dose of 20-30 μg of melphalan sounds to be safe and effective for refractory and recurrent vitreous seeds.μg of melphalan sounds to be safe and effective for refractory and recurrent vitreous seeds.
Authors: Carol L Shields; Carlos G Bianciotto; Pascal Jabbour; Aparna Ramasubramanian; Sara E Lally; Gregory C Griffin; Robert Rosenwasser; Jerry A Shields Journal: Arch Ophthalmol Date: 2011-06-13
Authors: Carol L Shields; Arman Mashayekhi; Angela K Au; Craig Czyz; Ann Leahey; Anna T Meadows; Jerry A Shields Journal: Ophthalmology Date: 2006-09-25 Impact factor: 12.079
Authors: Jasmine H Francis; David H Abramson; Marie-Claire Gaillard; Brian P Marr; Maja Beck-Popovic; Francis L Munier Journal: Ophthalmology Date: 2015-03-18 Impact factor: 12.079
Authors: Ankit Singh Tomar; Paul T Finger; Brenda Gallie; Tero Kivelä; Ashwin Mallipatna; Chengyue Zhang; Junyang Zhao; Matthew Wilson; Rachel Brennan; Michala Burges; Jonathan Kim; Jesse L Berry; Rima Jubran; Vikas Khetan; Suganeswari Ganeshan; Andrey Yarovoy; Vera Yarovaya; Elena Kotova; Denis Volodin; Yacoub Yousef; Kalle Nummi; Tatiana L Ushakova; Olga V Yugay; Vladimir G Polyakov; Marco Antonio Ramirez-Ortiz; Elizabeth Esparza-Aguiar; Guillermo L Chantada; Paula Schaiquevich; Adriana C Fandiño; Jason C Yam; Winnie W Lau; Carol P Lam; Phillipa Sharwood; Sonia Moorthy; Quah Boon Long; Vera Adobea Essuman; Lorna A Renner; Ekaterina Semenova; Jaume Català-Mora; Maria Correa Llano; Elisa Carreras Journal: Br J Ophthalmol Date: 2021-08-02 Impact factor: 5.908
Authors: Yacoub A Yousef; Mays Al Jboor; Mona Mohammad; Mustafa Mehyar; Mario D Toro; Rashed Nazzal; Qusai H Alzureikat; Magdalena Rejdak; Mutasem Elfalah; Iyad Sultan; Robert Rejdak; Maysa Al-Hussaini; Ibrahim Al-Nawaiseh Journal: Front Pharmacol Date: 2021-07-12 Impact factor: 5.810